Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of BBP-418 in LGMD2I/R9
2024-000202-16Phase 2
- Sponsor
- ML Bio Solutions
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by ML Bio Solutions. Primary endpoint: Treatment-emergent adverse events leading to dose decrease or discontinuation.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on 2024-000202-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000202-16.